The Cold Chain Pivot: Why Investors Are Quietly Abandoning Farm-Gate Apps
43 KEY POINTS Investors are shifting capital away from asset-light farm-gate marketplace apps toward cold chain infrastr…
Commodity costs divide Unilever and Beiersdorf on beauty pricing in Q3
Unilever and Beiersdorf’s respective Q3 2026 financial results reveal opposite approaches to pricing as the multinational consumer goods giants navigate rising commodity costs.
Ghana Opens $10,000 Pitch Competition for Young Agritech and Agribusiness Founders
3 Ghana’s BRIDGE-in Agriculture Pitch Competition 2026 offers US$10,000 in total grant funding to support eligible young…
Haut.AI SkinFM and SkinBench tackle false alarms in AI skin analysis
Haut.AI has unveiled its Skin Foundation Model (SkinFM), an image-based AI foundation model trained on over four million real skin images. It enables the company to develop customized skin measurements and analysis capabilities faster for beauty brands.
Givaudan brings bio-based dimethicone alternative to hair care
Givaudan Active Beauty has released SensoTrue DM5, a bio-based emollient alternative to 5 cSt dimethicone (DM5 silicone). The ingredient was developed via a combination of white biotechnology and green chemistry.
Exogenus secures €13M EU consortium backing for secretome therapy in osteoarthritis
The ExoCordOA consortium brings together 10 organizations, including Lonza, the UK charity Anthony Nolan, Eliquent Life Sciences, iLoF, Utrecht University, University Medical Center Utrecht, Maastricht University Medical Center+, Image Analysis Group and ReumaNederland. Funding will support Phase 1 and Phase 2 development of EXO-101, alongside work on manufacturing, quality control and regulatory requirements.
Vytrus Biotech spotlights plant-based PDRN for hair regeneration
Vytrus Biotech has revealed the first quantifications of Phyto-PDRN and ExoPDRN (polydeoxyribonucleotide) naturally present in its hair growth active, Capilia Longa.
Idorsia launches redesigned Fabry disease trial with Nxera backing
Fabry disease and lucerastat: Fabry disease is a rare inherited disorder caused by mutations in the GLA gene. Patients lack enough functioning alpha-galactosidase A, an enzyme that normally breaks down a fatty substance called globotriaosylceramide (Gb3). As Gb3 accumulates in cells, it progressively damages organs, particularly the kidneys, heart and nervous system. Patients can experience nerve pain and, over time, develop kidney failure, heart problems or stroke.
Seppic triples Ceramosides production capacity as nutricosmetics grow
Seppic has tripled the production capacity of its Ceramosides range in its Lons, France, facility. The company inaugurated a 1,400-square-meter building at the eight-hectare site. The new production unit aims to meet growing demand for purified natural actives in cosmetics and nutraceuticals.
Atlas Bio launches with $12.5M to eliminate animal testing and simulate Phase 2 trials
Why it matters: The techbio startup from Basel wants to help drugmakers identify promising diseases and patient groups before committing to expensive Phase 2 trials. Its broader claim — that simulations can replace those trials — remains to be demonstrated.